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receiving antithrombotic therapy. However, the use of VKA was not optimal in elderly
patients and better prophylactic strategies may be warranted for them .
1129-217 A Decision-Tree Model Comparing First-Line Electrical 
Cardioversion to Ibutilide With or Without Magnesium 
Prophylaxis in the Treatment of Atrial Fibrillation
Craig I. Coleman, James S. Kalus, C. Michael White, Jeffrey Kluger, University of 
Connecticut, Storrs, CT, Hartford Hospital, Hartford, CT
Background: Ibutilide is cost-effective when compared to first-line electrical cardiover-
sion (EC) for atrial fibrillation (AF); however, these results are sensitive to alterations in
conversion rate. Prophylactic magnesium augments the efficacy of ibutilide as demon-
strated by an increased rate of successful conversion. The objective of this evaluation
was to compare the costs associated with first-line EC and ibutilide in the presence and
absence of magnesium prophylaxis for the conversion of AF. Methods: A decision-tree
model was developed to estimate the cost-effectiveness of first-line EC compared to
ibutilide with or without prophylactic intravenous magnesium sulfate followed by EC in
those patients who do not convert. Conversion rates for patients receiving ibutilide with or
without magnesium were based upon results of a multi-center, retrospective, cohort
study (n=319). Healthcare utilization costs including drugs, intravenous admixture and
administration, EC, electrocardiographs and physicians’ fees were based upon actual
costs from our institution. Cost-effectiveness was calculated by multiplying the cost of a
successful and unsuccessful outcome by their probability of occurrence and then adding
these two figures to determine total cost. Results: Ibutilide+magnesium was found to be
the most cost-effective for conversion of AF (see figure). Conclusion: The decision-tree
model suggests that ibutilide+magnesium is more cost-effective than ibutilide alone or
first-line EC. 
1129-218 Ibutilide Improves Cardioversion Success Rates in 
Patients on Chronic Amiodarone Therapy With 
Persistent Atrial Fibrillation
Jenny C. Hu, Kelly Machuca, Shelley DePeralta, Bramah Singh, Zenaida Feliciano, VA 
Greater Los Angeles Healthcare System, Los Angeles, CA
Background: Atrial fibrillation (AF) is the most common arrhythmia, affecting approxi-
mately 2.2 million people in the United States. A combination of amiodarone and ibutilide
has been used with results suggesting an additive or synergistic effect on AF conversion.
Methods: We retrospectively studied 90 consecutive patients with persistent AF receiv-
ing oral amiodarone therapy who elected for electrical cardioversion. Patients underwent
either direct current cardioversion (DCC) (Group A, n=67) or DCC with ibutilide pretreat-
ment (Group B, n=23). To evaluate the effect of AF duration on DCC success rate,
patients were further divided into AF duration < 1 year (Group A1, n=30 and Group B1,
n=4) and AF duration > 1 year (Group A2, n=37 and Group B2, n=19). Chi-square analy-
sis was used to evaluate the statistical significance (set at p<0.05) between groups.
Results:
All patients were male, mostly hypertensive (86%) and age 64 ± 9.6 years, body mass
index 34 ± 8.1 kg/m2, left atrial size 52 ± 8.4 mm, ejection fraction 52 ± 10 %, and AF
duration 2.8 years ± 3.1 years. DCC success rates were 60% in Group A and 87% in
Group B (p=0.02). A trend for DCC success rate improvement with ibutilide was seen in
patients with AF duration > 1 year (Group A2=57% vs. Group B2=84%, p=0.07). One
patient in the ibutilide pretreatment group developed torsade de pointes.
Conclusion: Ibutilide pretreatment for DCC may be a safe and effective method of
improving DCC success rates in patients with long duration persistent AF receiving amio-
darone therapy. 
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1130-207 Prevalence and Spectrum of Mutations in the Cardiac 
Ryanodine Receptor in Patients Referred for Long QT 
Syndrome Genetic Testing
Laura J. Kopplin, David J. Tester, Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background: Pathogenic mutations in the gene, RYR2, encoding the cardiac ryanodine
receptor cause type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1).
There is phenotypic overlap between the clinical presentation of CPVT and long QT syn-
drome (LQTS). Because the diagnosis of CPVT can be elusive, we sought to determine
the spectrum and prevalence of RYR2 mutations in a cohort of unrelated patients
referred specifically for LQTS genetic testing.
Methods: Since 1997, nearly 500 unrelated patients have been referred to Mayo Clinic’s
Sudden Death Genomics Laboratory for LQTS genetic testing. Putative pathogenic
mutations in the known LQTS-causing genes have been identified in approximately 50%
of the cases. Mutational analysis of 18 exons of RYR2 previously implicated in CPVT was
performed on genomic DNA from 240 genotype-negative subjects using polymerase
chain reaction, denaturing high performance liquid chromatography, and direct DNA
sequencing.
Results: Seventeen distinct RYR2 mutations (16 missense, 1 duplication insertion, 15
novel) were found in 20 out of 240 genotype-negative subjects (8.3%). None of these
mutations were present in 400 reference alleles. Two mutations localized to the
FKBP12.6 binding domain. Upon review of the clinical records, the referral diagnosis for
19 out of 20 patients was “atypical” or “borderline” LQTS rather than CPVT. None of the
individuals displayed diagnostic QT prolongation (QTc > 470 ms).
Conclusion: Putative pathogenic CPVT1-causing mutations in RYR2 were detected in
nearly 10% of unrelated and LQTS genotype-negative patients who were referred for
LQTS genetic testing. These findings suggest that CPVT may be under-recognized
among physicians referring patients with a suspected channelopathy. A diagnosis of
“atypical LQTS” may warrant consideration of CPVT and analysis of RYR2 if the primary
LQTS-causing channel screen is negative.
1130-208 Diagnostic Value of the Ajmaline Test Based on the 
Gene Analysis in Concealed Brugada Syndrome
Kui Hong, Kiyotaka Matsuo, Antonio Berruezo Sanchez, Matteo Vatta, Jeff Towbin, Josep 
Brugada, Pedro Brugada, Carlos Piñero Galvez, Charles Antzelevitch, Ramon Brugada, 
Masonic Medical Research Laboratory, Utica, NY
Background Brugada syndrome is an arrhythmogenic disease caused in part by muta-
tions in the cardiac sodium channel gene, SCN5A. The electrocardiogram in Brugada
syndrome is variable over time up to the point of normalization in some individuals. Diag-
nosis of possible affected individuals is performed with the use of sodium channel-block-
ing agents which unmask the EKG abnormality. However, validation of the testing has not
been performed. The use of genetic data as a gold standard in large families allows to
examine the effectiveness of ajmaline for diagnosis.
Methods We collected 4 large families with a total of 128 members. Ninety members
were relatives at possible risk of Brugada syndrome. Sixteen had a positive EKG at base-
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line. The remaining 74 subject (31 males and 43 females), who had negative ECG at
baseline, received intravenous class 1 blocker (ajmaline 1mg/kg). The ECG was consid-
ered positive if the ST-segment in leads V1 and V2 (V3) was elevated >0.2 mV and
showed “coved”-type morphology before or after the infusion of ajmaline. The exons of
SCN5A were screened in the families using direct sequencing.
Results All 4 families had a mutation in SCN5A. The 16 subjects with positive ECG at
baseline had SCN5A Mutation. Of the 74 individuals who received ajmaline test there
were 29 positives and 45 negatives. Two positives did not have the mutation, and 7 nega-
tives had the mutation. All results on the ajmaline test are shown in the table. The Sensi-
tivity, specificity, and positive or negative predictive value of the test is 79.4%, 95.0%, and
93.1% or 84.4%, respectively.
(male/female).
Conclusion A specificity of 95% and a sensitivity of close to 80% indicate that the ajma-
line test is very valuable in the diagnosis of SCN5A carriers in families with Brugada syn-
drome. There are two false positives that raises an issue of a second gene in the family
or an iatrogenic false positive.
1130-219 Conus Branch Ischemia Provokes Brugada-Type ST- 
Segment Changes in Patients With Coronary Artery 
Disease
Masaru Yamaki, Takeshi Nishiura, Toru Kaji, Mitsuru Gima, Naoki Funayama, Katsumi 
Ohbori, Nobuyuki Sato, Yuichiro Kawamura, Naoyuki Hasebe, Kenjiro Kikuchi, Hokkaido 
Cardiovascular Hospital, Sapporo, Japan, Asahikawa Medical College, Asahikawa, 
Japan
Recently, the intriguing coexistence of vasospastic angina and Brugada syndrome have
been reported in some cases. However, the mechanistic relationship between Brugada
type ECG abnormalities and ischemia of the right ventricular outflow tract has not been
fully elucidated. Here we present four cases with coronary artery disease who presented
with ECG abnormalities induced by ischemia of the conus branch (CB) of the right coro-
nary artery. The twelve-lead ECGs at rest showed normal sinus rhythm in all cases. Sur-
prisingly, the saddle back-type ST segment elevation in leads V1-V3 was observed either
during the percutaneous transluminal angioplasty procedure of the proximal right coro-
nary artery or with an intracoronary ergonovine injection into the right coronary artery.
The coronary angiogram exhibited a total occlusion or 99% stenosis with a delay in the
CB and significant stenosis of the proximal right coronary artery in three cases and coro-
nary vasospasms of the CB and right coronary artery in the remaining case. These Bru-
gada-type ECG changes reversibly disappeared after cessation of the ischemia from the
CB lesion. In the fourth patient which had vasospasms of the right coronary artery,
remarkable coved-type ST segment elevation was also induced by the class IC antiar-
rhythmic agent, pilsicainide, suggesting a concealed form of Brugada syndrome. These
results suggest that the free wall of the right ventricular outflow tract supplied by the CB
plays a pivotal role in the genesis of the Brugada-type ECG changes, and the ischemia
from CB lesions, at least in part, contributes to the Brugada-type ST segment changes.
1130-220 Brugada-Type Electrocardiographic Pattern and ST-
Segment Alternans in Right Precordial Leads During 
Percutaneous Coronary Intervention of the Proximal 
Right Coronary Artery
Naoki Fujimoto, Chikaya Omichi, Takafumi Koji, Atsushi Kawasaki, Shigeki Kato, 
Atsunobu Kasai, National Mie Central Hospital, Hisai, Japan
Background: Brugada syndrome is characterized by a right bundle branch block pattern
and ST segment elevation in the right precordial leads. The Brugada-type electrocardio-
graphic (ECG) pattern can be observed in asymptmatic healthy patients (pts) or condi-
tions other than true Brugada syndrome. The mechanisms of Brugada-type ECG pattern
are not fully understood.
Methods: We performed percutaneous coronary intervention (PCI) of proximal right cor-
onary artery (RCA) for ischemic heart diseases in 12 pts. No significant stenosis was
observed in left coronary arteries in all pts. The ST changes were evaluated during PCI.
Angiographical changes were carefully observed from major branches of RCA to small
branches during PCI. We measured ST elevation in right precordial leads with class I
antiarrhythmic drug administration: pilsicainide 50 mg (pure sodium channel blocker)
after PCI. ST changes were compared with true Brugada syndrome (n=5).
Results: Brugada-type ECG was observed in 5 pts (42%) but not in 7 pts (58%) during
PCI of proximal RCA. All 5 pts who had Brugada-type ECG demonstrated ST segment
alternans from coved shape to saddle back shape during PCI. These ECG changes
returned to normal after PCI. These pts who had Brugada-type ECG with ST alternans
demonstrated selective small RV branch occlusion or vasospasm during PCI, which per-
fused RV anterior wall or RV outflow. However pts without Brugada-type ECG did not
show RV branch occlusion. The class I antiarrhythmic drug administration showed no sig-
nificant ST elevation both in pts with Brugada-type ECG and in pts without Brugada-type
ECG (0.70±0.54mv, vs 0.46±0.21mv, p=NS). There was a significant difference in ST
elevation between pts with Brugada-type ECG during PCI and pts with true Brugada syn-
drome. (0.70±0.54mv, vs 2.86±0.61mv, p<0.05)
Conclusions: The pts who had RV branch occlusion during PCI showed Brugada-type
ECG and ST alternans. Sodium channel impairment was not associated with these ECG
changes. ST alternans might be considered as prerequisites before developing ventricu-
lar arrhythmia. These data suggest that merely ischemia of small RV branch could be
one of the different entities showing Brugada-type ECG from true Brugada syndrome.
1130-221 Prior Ischemia Enhances Arrhythmogenicity in Isolated 
Canine Ventricular Wedge Model of Long QT 3
Norihiro Ueda, Douglas P. Zipes, Jiashin Wu, Krannert Institute of Cardiology, 
Indianapolis, IN
Background: Ventricular tachyarrhythmias (VTs) occur frequently in patients having long
QT syndrome (LQTS) or after acute myocardial ischemia. However, the synergistic
effects of ischemia and LQTS on arrhythmia development are unclear. We evaluated the
contribution of a prior episode of ischemia on the arrhythmogenicity of the LQTS. Meth-
ods : Using a 256-channel optical mapping system, we mapped action potentials on the
cut-exposed transmural surfaces of arterially perfused muscle wedges isolated from
canine left ventricular free walls and recorded their transmural electrocardiogram (ECG).
Results: We observed that 40 minutes of global ischemia (no perfusion) followed by 60
minutes of reperfusion, at which time action potential duration (APD) and conduction
velocity had recovered, significantly enhanced the APD prolongation produced by anem-
one toxin II (ATX-II, 20 nmol/L), which delays the inactivation of sodium current and pro-
duces type 3 LQTS. The combination of ischemia, reperfusion, and ATX-II caused early
afterdepolarization (EAD) development in 8/8 wedges (100%) and spontaneous VTs in 7/
8 wedges (87.5%) at a time when perfusion was normal. We observed epicardial, midmy-
ocardial, and endocardial occurrences of EADs in 1, 7, and 4 wedges, respectively. Focal
EAD and reentry were responsible for 73% and 18% of the repetitive activations in the
VTs. Reentry, transmural APD heterogeneity, and EADs originating from multiple focal
sites generated polymorphic VT in the transmural ECG. In contrast, neither EADs (0%)
nor VTs (0%) occurred in 8 control wedges having the same protocol except without
ischemia (ATX-II only), and VT occurred in 2/10 wedges (20%) after ischemia but before
ATX-II (ischemia only). Conclusions: A prior episode of acute ischemia, even after
apparent electrophysiologic recovery, enhances the arrhythmogenicity of LQTS induced
by ATX-II through the development of EADs and reentry. The results imply that patients
with both LQTS and ischemic heart disease or those with myocardial ischemia or infarc-
tion who take medications that prolong APD could be at increased risk for developing VT.
1130-222 High Incidence of Prolonged QTc in Asthmatics
Craig D. Williams, Richard J. Kovacs, Sandip Sheth, Cindy Calley, Purdue University 
School of Pharmacy, Indianapolis, IN, Indiana University School of Medicine, 
Indianapolis, IN
Background: A high incidence of asthma has been reported amoung registrants of the
International Long QT Syndrome (LQTS) Registry. Asthma is associated with a risk of
sudden death that is not always explained by pulmonary findings at autopsy.
Objective: To determine if a higher than expected rate of LQTS occurs in an identified
cohort of patients with asthma.
Methods: Patients over 18 years of age admitted to a city-county hospital with a primary
diagnosis of asthma between February 1, 2001 and September 30, 2002 were identified.
Patients with a documented ECG performed since December 2000 were enrolled. A sin-
gle cardiologist read all ECGs to determine the QT interval which was then corrected with
a Bazetts calculation to determine QTc. Lead II was used for QT interval measurement. If
lead II was unreadable, lead V5 or aVF was used. The reported, uncorrected QT interval
was an average of the measurement of three different complexes in the same lead. QTc
results were compared to a published cohort of 420 non-asthamtic adults. Prolonged
QTc was defined as > 455 msec in men and > 475 msec in women which defined the
upper 1% of QTc in the non-asthmatic cohort. No patients were on anti-psychotic or anti-
arrhythmic medications. Patients were excluded from analysis if they had a previous doc-
umented myocardial infarction (1 patient), or documented hypokalemia (2 patients),
hypocalcemia (1 patient), or hypomagnesemia (1 patient) within 1 week of their recorded
ECG.
Results: 193 patients were identified, 130 of whom had a readable ECG. The incidence
of prolonged QTc was 19.8% (17/86) in females, 28.2% (11/39) in males and 22.4% (28/
125) overall. Compared to the 1% incidence of prolonged QTc in the published non-asth-
matic cohort, a one sample test of proportions was statistically significant for all 3 data
sets (p< 0.001 for male, female and overall).
Conclusion: Asthmatics appear to have an unusually high incidence of prolonged QTc
intervals.
1130-223 Utility of Adenosine in Differentiation of Patients With 
Right Ventricular Outflow Tract Tachycardia and 
Arrhythmogenic Right Ventricular Dysplasia
Sei Iwai, Kenneth M. Stein, Steven M. Markowitz, Suneet Mittal, Amit B. Guttigoli, Bindi 
K. Shah, Ravi K. Yarlagadda, Bruce B. Lerman, Cornell University Medical Center, New 
York, NY
Background: Patients with right ventricular outflow tract (RVOT) tachycardia and arrhyth-
mogenic right ventricular dysplasia (ARVD) can both present with left bundle branch
block inferior axis ventricular tachycardia (VT). However, the management and prognosis
of the two entities is very different, and clear differentiation of these etiologies of VT
would be clinically useful. Termination with adenosine is thought to be specific for arrhyth-
mias due to cyclic AMP-mediated triggered activity; adenosine, with rare exceptions, has
no effect on arrhythmias due to reentry. Methods and Results: We compared the sensi-
tivity of VT to adenosine in patients with RVOT tachycardia and those with ARVD. VT was
sensitive to adenosine in 35 of 40 patients with RVOT tachycardia. Of note, 2 of the 5 pts
with adenosine-insensitive VT were subsequently found to have a somatic mutation in
the inhibitory G-protein, Gi, impairing intracellular cyclic AMP regulation. In contrast, 10
of 10 patients with ARVD had VT which was adenosine-insensitive. Therefore, the sensi-
tivity of adenosine termination of VT in identifying pts with RVOT tachycardia was 88%
while the specificity was 100%. Conclusions: These findings suggest that response of
VT to adenosine may be a simple and effective clinical tool for differentiating patients with
RVOT tachycardia from those with VT due to ARVD.
